(MAIA - MAIA BIOTECHNOLOGY INC)

company profile

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Maia Biotechnology (MAIA) is trading at 1.3

Open Price
1.28
Previous close
1.3
Previous close
1.3
P/E Ratio
0
Sector
Health Care
Shares outstanding
61750308
Primary exchange
American
ISIN
US5526411021